Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Multiple Myeloma 55Recurrence 10Neoplasms, Plasma Cell 3Smoldering Multiple Myeloma 2Hematologic Neoplasms 2Primary Myelofibrosis 1Polycythemia Vera 1Neoplasms 1Lymphoma 1Leukemia, Plasma Cell 1Leukemia, Myeloid, Acute 1Immunoglobulin Light-chain Amyloidosis 1

Interventions

fludarabine phosphate 29Peripheral Blood Stem Cell Transplantation 26Cyclophosphamide 25ruxolitinib 22Busulfan 21Tacrolimus 16Whole-Body Irradiation 15Mycophenolic Acid 14Methotrexate 13Cyclosporine 12Antilymphocyte Serum 11Hydroxyurea 10Aspirin 9fludarabine 8Filgrastim 8Melphalan 7Etoposide 7Decitabine 7peginterferon alfa-2a 6Imatinib Mesylate 6Cytarabine 611-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 6givinostat hydrochloride 5givinostat 5Radiotherapy 5Prednisone 5Carboplatin 5Biopsy 5Topotecan 4Thiotepa 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Polycythemia Vera × elotuzumab × Clear all
NCT04517851 2026-01-13

Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
15 enrolled
Myeloid

Polycythemia Vera, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡